1. Home
  2. GCV vs ALXO Comparison

GCV vs ALXO Comparison

Compare GCV & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Convertible and Income Securities Fund Inc. (The)

GCV

Gabelli Convertible and Income Securities Fund Inc. (The)

HOLD

Current Price

$4.37

Market Cap

85.1M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.18

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCV
ALXO
Founded
1988
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.1M
68.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GCV
ALXO
Price
$4.37
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.30
AVG Volume (30 Days)
57.9K
210.1K
Earning Date
01-01-0001
03-05-2026
Dividend Yield
13.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.15
$0.40
52 Week High
$4.58
$2.27

Technical Indicators

Market Signals
Indicator
GCV
ALXO
Relative Strength Index (RSI) 61.43 42.28
Support Level $4.31 $1.07
Resistance Level $4.34 $1.56
Average True Range (ATR) 0.07 0.12
MACD 0.01 0.00
Stochastic Oscillator 94.41 21.43

Price Performance

Historical Comparison
GCV
ALXO

About GCV Gabelli Convertible and Income Securities Fund Inc. (The)

GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: